GFH375 combined with cetuximab or chemotherapy for KRAS G12D–mutant solid tumors
Official title: A Multicenter, Open-Label, Phase Ib/II Clinical Study to Explore the Efficacy, Pharmacokinetics and Safety/Tolerability of GFH375 in Combination With Cetuximab or Chemotherapy in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutation
Run by Genfleet Therapeutics (Shanghai) Inc. · NCT07259590 · Data updated 2026-11-12
This tests whether adding GFH375 to cetuximab or to standard chemotherapy helps people with advanced solid tumors that have a KRAS G12D mutation.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 126 (estimated) |
| Sponsor | Genfleet Therapeutics (Shanghai) Inc. Industry-sponsored |
| Drugs / interventions | radiation, Cetuximab |
| Locations | 4 sites (Beijing, Beijing Municipality and 3 other locations) |
| Status | Recruiting |
| Started | October 21, 2025 |
| Main results expected | July 2027 |
| Study ends | July 2027 |
| Registry record updated | December 2, 2025 |
| Trial ID | NCT07259590 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with histologically or cytologically confirmed unresectable or metastatic solid tumors with a KRAS G12D mutation, measurable disease by RECIST v1.1, adequate organ function, and who have failed or are unsuitable for standard therapies.
✕Probably not a fit
Patients without the KRAS G12D mutation, those with symptomatic brain metastases or other excluded conditions, or those who do not meet the required performance status or organ-function criteria are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase Ib/II trial testing two combination regimens: GFH375 plus cetuximab (Regimen A) and GFH375 plus AG chemotherapy (Regimen B) in patients with advanced, unresectable or metastatic solid tumors harboring KRAS G12D mutations. Phase Ib focuses on safety, tolerability and pharmacokinetics of the combinations while exploring early signs of activity. Phase II expands the evaluation of efficacy, continued safety monitoring and pharmacokinetics, and examines relationships between biomarkers and clinical outcomes. Eligible participants must have measurable disease and have exhausted or be unsuitable for standard treatment options.
Why it matters
Potential benefit: If successful, this could provide a new targeted treatment option that controls tumor growth in patients with KRAS G12D–mutant cancers.
How similar studies have gone: Targeting KRAS G12D is relatively novel with limited clinical proof to date, though KRAS-directed approaches (notably for G12C) have shown clinical benefit and preclinical data support efforts against G12D.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Voluntarily participate in the study and sign the informed consent form. 2. Participants receiving Regimen A must be ≥ 18 years old when signing the informed consent form, and participants receiving Arm B must be 18 - 75 years old. 3. Histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumors, with KRAS G12D mutation. 4. Failed standard systemic treatment, or intolerant to standard treatment, or unsuitable for standard treatment, or no standard treatment available. 5. At least one measurable lesions according to RECIST v1.1 6. Participants receiving Regimen A must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 - 2; participants receiving Regimen B must have an ECOG PS score of 0 - 1. 7. Have sufficient organ function. Exclusion Criteria: 1. Symptomatic brain metastasis, leptomeningeal metastasis, spinal cord compression, or primary brain tumor. 2. Presence of known coexisting other cancer driver genes. 3. Previous or active history of clinically significant cardiovascular dysfunction. 4. Presence of active infection. 5. History of central nervous system (CNS) diseases. 6. Presence of clinically significant interstitial lung disease, radiation pneumonitis, or immune-related pneumonitis requiring treatment. 7. Newly diagnosed deep vein thrombosis or pulmonary embolism within 3 months before the first administration of the study treatment. 8. Presence of uncontrolled or symptomatic pleural effusion, ascites, or pericardial effusion. 9. Having received major surgery within 28 days before the start of the study treatment; having experienced major trauma within 14 days before the start of the study treatment; or planning to undergo major surgery during the study period. 10. Having received radiotherapy within 4 weeks before the start of the study treatment, or having received palliative radiotherapy for bone metastatic lesions within 2 weeks before the start of the study treatment.
Where it's running
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China Recruiting -
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China Not yet recruiting -
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China Not yet recruiting -
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China Not yet recruiting
Study contacts
- Principal investigator: Lin Shen, MD — Peking University Cancer Hospital & Institute
- Study coordinator: Yolanda Zeng
- Email: yaozeng@genfleet.com
- Phone: +8618073129952
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GFH276 with Cetuximab or chemotherapy in RAS-mutated solid tumors and PDAC
This study tests whether GFH276 combined with cetuximab or standard chemotherapy can help adults with advanced solid tumors or pancreatic cancer that carry a RAS mutation.
-
Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer
This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer
In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.
-
Cetuximab bioequivalence test in healthy men
This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.